Amendments to the Claims

The listing of claims will replace all prior versions and listings of claims in the application.

Listing of Claims:

1.-22. (Canceled).

23. (Currently Amended) A method for inhibiting the ~~formation or~~ growth of blood-born tumors sensitive to thalidomide in a human comprising administering to said human ~~an~~ a therapeutically effective amount of thalidomide.

24. (Canceled).

25. (Previously Presented) The method of Claim 23 wherein the thalidomide is administered orally, sublingually, or buccally.

26. (Previously Presented) The method of Claim 23 wherein the thalidomide is administered in the form of a tablet or capsule.

27. (Previously Presented) The method of Claim 23 wherein the thalidomide is administered in an amount between approximately 0.1 and approximately 300 mg/kg/day.

28. (Previously Presented) The method of Claim 23 wherein the thalidomide is administered in an amount between approximately 0.5 and 50 mg/kg/day.

29. (Previously Presented) The method of Claim 28 wherein the thalidomide is administered in an amount between approximately 1 and approximately 10 mg/kg/day.

30. (Previously Presented) The method of Claim 23 wherein the human is at risk for developing a tumor.

31. (Previously Presented) The method of Claim 23 wherein the thalidomide is administered in the form of a lozenge, a cachet, a solution, a suspension, an emulsion, or a powder.

32. (Canceled).

33. (Previously Presented) The method of Claim 23 wherein the human has a primary tumor.

34. (Currently Amended) The method of Claim 33 wherein the primary tumor is ~~a Kaposi's sarcoma, hemangioma, rhabdomyosarcoma, retinoblastoma, Ewings's sarcoma, neuroblastoma, osteosarcoma,~~ leukemia~~, neurofibroma, pyogenic granulosum, or breast cancer~~.

35. (Previously Presented) The method of Claim 33 wherein the thalidomide is administered orally, sublingually, or buccally.

36. (Previously Presented) The method of Claim 33 wherein the thalidomide is administered in an amount between approximately 0.1 and approximately 300 mg/kg/day.

37. (Previously Presented) The method of Claim 36 wherein the thalidomide is administered in an amount between approximately 0.5 and approximately 50 mg/kg/day.

38. (Previously Presented) The method of Claim 37 wherein the thalidomide is administered in an amount between approximately 1 and approximately 10 mg/kg/day.

39. (Previously Presented) The method of Claim 33 wherein the thalidomide is administered in the form of a tablet or capsule.

40. (Previously Presented) The method of Claim 33 wherein the thalidomide is administered in the form of a lozenge, a cachet, a solution, a suspension, an emulsion, or a powder.

41. -58. (Canceled).

59. (Previously Presented) The method of Claim 23 wherein the thalidomide is administered rectally, vaginally, transdermally, topically, basally, or parenterally.

60. (Previously Presented) The method of Claim 23 wherein the thalidomide is administered in the form of an aerosol, a spray, a suppository, a tampon, a pessary, a pastille, an ointment, a cream, a paste, a foam or a gel.

61. (Previously Presented) The method of Claim 33 wherein the thalidomide is administered rectally, vaginally, transdermally, topically, basally, or parenterally.

62. (Previously Presented) The method of Claim 33 wherein the thalidomide is administered in the form of an aerosol, a spray, a suppository, a tampon, a pessary, a pastille, an ointment, a cream, a paste, a foam or a gel.

63.-70. (Canceled)

71. (Currently Amended) The method of Claim 25, or 35~~, 43 or 52~~, wherein the thalidomide is administered orally.

72. (New) The method of Claim 71, wherein the thalidomide is administered in the form of a capsule.